The Department of Health has welcomed the arrival of the first batch of Lenacapavir, a six-monthly injectable designed to prevent HIV infections. A total of 37,920 doses has been received, with the medication expected to play a key role in reducing new infections, particularly among high-risk groups.
The rollout supports South Africa’s broader goal of ending AIDS as a public health threat by 2030.
National Department of Health spokesperson Foster Mohale described the development as significant, saying, “This is a game changer. We believe it’s going to revolutionise our response to HIV as a country, and globally.” He added that the drug is expected to make “a huge impact” in efforts to curb the spread of HIV.
Mohale also highlighted South Africa’s contribution to the development of Lenacapavir, noting that while the drug was developed by US-based pharmaceutical company Gilead, local participation in clinical trials was crucial. “South Africa participated in the clinical trials, which proved that this drug is highly effective in preventing HIV infection,” he said.
Listen to the interview below:
VOC News
Photo: Pixabay
